chr7:17171814:> Detail (hg19)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr7:17,171,814-17,385,774 |
| hg38 | chr7:17,132,190-17,346,150 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
| Score | Disease name | Description | Source | Pubmed | Links |
|---|---|---|---|---|---|
| <0.001 | Carcinoma, Transitional Cell | NA | BeFree | Detail | |
| <0.001 | Uterine Cervical Neoplasm | NA | BeFree | Detail | |
| <0.001 | choriocarcinoma | NA | BeFree | Detail | |
| 0.002 | colitis | NA | BeFree | Detail | |
| <0.001 | ulcerative colitis | NA | BeFree | Detail | |
| 0.002 | Colorectal Neoplasms | NA | GAD | Detail | |
| <0.001 | dermatitis | NA | BeFree | Detail | |
| <0.001 | Dermatitis, Atopic | NA | BeFree | Detail | |
| 0.120 | contact dermatitis | NA | CTD_human | Detail | |
| <0.001 | Diabetic Angiopathies | NA | BeFree | Detail | |
| <0.001 | Eczema | NA | BeFree | Detail | |
| <0.001 | Experimental Autoimmune Encephalomyelitis | NA | BeFree | Detail | |
| 0.008 | endometriosis | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | Eosinophilia | NA | BeFree | Detail | |
| <0.001 | Fatty Liver | NA | BeFree | Detail | |
| <0.001 | glioblastoma | NA | BeFree | Detail | |
| <0.001 | Glioma | NA | BeFree | Detail | |
| 0.120 | Growth Disorders | NA | CTD_human | Detail | |
| <0.001 | Head and Neck Neoplasms | NA | BeFree | Detail | |
| 0.120 | congenital heart defects | NA | BeFree,CTD_human | Detail | |
| 0.120 | Cardiomegaly | NA | CTD_human | Detail | |
| <0.001 | hepatitis | NA | BeFree | Detail | |
| <0.001 | hepatitis A | NA | BeFree | Detail | |
| <0.001 | hydronephrosis | NA | BeFree | Detail | |
| <0.001 | hyperglycemia | NA | BeFree | Detail | |
| 0.120 | Hypertensive disease | NA | BeFree,CTD_human | Detail | |
| 0.120 | Hyperventilation | NA | CTD_human | Detail | |
| 0.121 | male infertility | NA | BeFree,CTD_human | Detail | |
| 0.123 | Inflammation | NA | CTD_human,LHGDN | Detail | |
| <0.001 | Inflammatory Bowel Diseases | AHR-related compounds might be the new and promising therapeutic medicaments for... | BeFree | 25799939 | Detail |
| 0.120 | Insulin resistance | NA | CTD_human | Detail | |
| 0.003 | Laryngeal neoplasm | NA | BeFree,GAD | Detail | |
| 0.003 | Fibroid Tumor | NA | BeFree,LHGDN | Detail | |
| 0.001 | leukemia | NA | BeFree | Detail | |
| <0.001 | Acute lymphocytic leukemia | NA | BeFree | Detail | |
| <0.001 | Acute Megakaryocytic Leukemias | NA | BeFree | Detail | |
| <0.001 | Myeloid Leukemia, Chronic | NA | BeFree | Detail | |
| 0.003 | Adult T-Cell Lymphoma/Leukemia | NA | BeFree,LHGDN | Detail | |
| 0.120 | Liver diseases | NA | CTD_human | Detail | |
| 0.126 | Liver neoplasms | We examined the expression kinetics of some of the aryl hydrocarbon receptor (Ah... | BeFree,CTD_human | 25637755 | Detail |
| 0.003 | Lung diseases | NA | LHGDN | Detail | |
| 0.003 | Chronic Obstructive Airway Disease | NA | BeFree,GAD | Detail | |
| 0.005 | Lung Neoplasms | NA | BeFree,GAD,LHGDN | Detail | |
| 0.005 | lymphoma | NA | BeFree,GAD,LHGDN | Detail | |
| 0.005 | Lymphoma, Non-Hodgkin | NA | BeFree,GAD | Detail | |
| <0.001 | malaria | NA | BeFree | Detail | |
| 0.001 | Malignant neoplasm of stomach | NA | BeFree | Detail | |
| <0.001 | medulloblastoma | NA | BeFree | Detail | |
| <0.001 | melanoma | NA | BeFree | Detail | |
| <0.001 | premature menopause | NA | BeFree | Detail | |
| 0.120 | Metabolic Diseases | NA | CTD_human | Detail | |
| 0.003 | multiple myeloma | Collectively, these data implicate polycyclic aromatic hydrocarbons and AhR in t... | BeFree,GAD | 24798859 | Detail |
| 0.120 | Necrosis | NA | CTD_human | Detail | |
| 0.120 | Neoplasm Invasiveness | NA | CTD_human | Detail | |
| 0.121 | Neoplasm Metastasis | NA | BeFree,CTD_human | Detail | |
| 0.120 | Neoplasms, Experimental | NA | CTD_human | Detail | |
| <0.001 | neuroblastoma | NA | BeFree | Detail | |
| <0.001 | Nevus | NA | BeFree | Detail | |
| 0.002 | Occupational Diseases | NA | GAD | Detail | |
| 0.002 | oligospermia | NA | GAD | Detail | |
| 0.001 | ovarian carcinoma | NA | BeFree | Detail | |
| <0.001 | Ovarian Cysts | NA | BeFree | Detail | |
| 0.120 | Pancreatic Neoplasm | NA | CTD_human | Detail | |
| 0.120 | Peripheral neuropathy | NA | CTD_human | Detail | |
| 0.001 | pituitary adenoma | Although AHR has been found differently expressed in pituitary adenomas, AHR gen... | BeFree | 24521362 | Detail |
| <0.001 | Pituitary Neoplasms | NA | BeFree | Detail | |
| 0.120 | pneumonia | NA | BeFree,CTD_human | Detail | |
| <0.001 | polyps | NA | BeFree | Detail | |
| 0.120 | Prostatic Neoplasms | NA | CTD_human | Detail | |
| <0.001 | psoriasis | NA | BeFree | Detail | |
| <0.001 | Signs and Symptoms, Respiratory | NA | BeFree | Detail | |
| 0.120 | silicosis | NA | CTD_human | Detail | |
| <0.001 | Dermatologic disorders | NA | BeFree | Detail | |
| <0.001 | Sleep disturbances | NA | BeFree | Detail | |
| 0.120 | Splenic Diseases | NA | CTD_human | Detail | |
| 0.120 | Splenomegaly | NA | CTD_human | Detail | |
| 0.123 | Stomach Neoplasms | NA | CTD_human,LHGDN | Detail | |
| <0.001 | Cerebrovascular accident | L-kynurenine/aryl hydrocarbon receptor pathway mediates brain damage after exper... | BeFree | 25359166 | Detail |
| 0.120 | Tachycardia | NA | CTD_human | Detail | |
| 0.120 | Tobacco use disorder | NA | CTD_human | Detail | |
| 0.120 | Ureteral Neoplasms | NA | CTD_human | Detail | |
| <0.001 | Uterine Fibroids | NA | BeFree | Detail | |
| 0.120 | Vascular Diseases | NA | CTD_human | Detail | |
| <0.001 | vitiligo | NA | BeFree | Detail | |
| <0.001 | diffuse large B-cell lymphoma | It is particularly interesting that BCL6 - regulated by AhR/ARNT and wild-type M... | BeFree | 25769544 | Detail |
| <0.001 | Lymphoma, Large-Cell, Follicular | NA | BeFree | Detail | |
| 0.002 | Neoplasms, Second Primary | NA | GAD | Detail | |
| <0.001 | Ovarian Failure, Premature | NA | BeFree | Detail | |
| <0.001 | Xeroderma Pigmentosum, Complementation Group D | We assessed polymorphisms in the aryl hydrocarbon receptor (AhR-Arg554Lys), null... | BeFree | 15459223 | Detail |
| 0.120 | Left Ventricular Hypertrophy | NA | CTD_human | Detail | |
| <0.001 | Small cell carcinoma of lung | NA | BeFree | Detail | |
| <0.001 | Atrophic condition of skin | NA | BeFree | Detail | |
| 0.121 | Adenocarcinoma of lung (disorder) | NA | BeFree,CTD_human | Detail | |
| <0.001 | Secondary malignant neoplasm of lung | NA | BeFree | Detail | |
| 0.001 | Tumor Progression | In conclusion AhR knockdown alters the expression of genes known to enhance or i... | BeFree | 24932473 | Detail |
| <0.001 | Carcinoma, Endometrioid | NA | BeFree | Detail | |
| <0.001 | Cystadenocarcinoma, Serous | NA | BeFree | Detail | |
| 0.002 | Squamous Cell Neoplasms | NA | GAD | Detail | |
| <0.001 | Angiofibroma | NA | BeFree | Detail | |
| 0.120 | Chronobiology Disorders | NA | CTD_human | Detail | |
| 0.120 | Dyslipidemias | NA | CTD_human | Detail | |
| 0.010 | Malignant neoplasm of lung | NA | BeFree,GAD | Detail | |
| 0.003 | age related macular degeneration | Collectively, our findings identify AhR as a regulator of multiple pathogenic pa... | BeFree,GAD | 25186463 | Detail |
| 0.120 | Hyperoxia | NA | CTD_human | Detail | |
| <0.001 | Parasitemia | NA | BeFree | Detail | |
| <0.001 | Chloracne | NA | BeFree | Detail | |
| <0.001 | Chronic nonspecific lung disease | NA | BeFree | Detail | |
| <0.001 | Xeroderma Pigmentosum, Complementation Group D | NA | BeFree | Detail | |
| 0.120 | Lung Injury | NA | CTD_human | Detail | |
| <0.001 | Carcinoma breast stage IV | NA | BeFree | Detail | |
| <0.001 | Liver and Intrahepatic Biliary Tract Carcinoma | NA | BeFree | Detail | |
| <0.001 | Squamous cell carcinoma of esophagus | NA | BeFree | Detail | |
| <0.001 | Conventional (Clear Cell) Renal Cell Carcinoma | Activation of aryl hydrocarbon receptor promotes invasion of clear cell renal ce... | BeFree | 25523818 | Detail |
| <0.001 | laryngeal squamous cell carcinoma | NA | BeFree | Detail | |
| 0.120 | Atrophic | NA | CTD_human | Detail | |
| <0.001 | Hyperplastic Polyp | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of liver | NA | BeFree | Detail | |
| <0.001 | Growth Hormone-Secreting Pituitary Adenoma | In this study, we evaluated patients with apparently sporadic GH-secreting pitui... | BeFree | 24521362 | Detail |
| <0.001 | Asthma attack | NA | BeFree | Detail | |
| 0.002 | Malignant neoplasm of prostate | NA | BeFree | Detail | |
| <0.001 | Hematologic Neoplasms | NA | BeFree | Detail | |
| <0.001 | Papillary neoplasm | NA | BeFree | Detail | |
| 0.001 | endometrial carcinoma | Aryl hydrocarbon receptor exogenous ligand 3-methylchoranthrene inhibited endome... | BeFree | 24817304 | Detail |
| 0.002 | dementia | NA | GAD | Detail | |
| <0.001 | Metabolic syndrome X | NA | BeFree | Detail | |
| <0.001 | Early Awakening | NA | BeFree | Detail | |
| 0.120 | Allergy to peanuts | NA | CTD_human | Detail | |
| 0.007 | Carcinogenesis | Aryl hydrocarbon receptor (AHR) pathway has a key role in cellular detoxificatio... | BeFree | 24521362 | Detail |
| 0.007 | Carcinogenesis | Collectively, our results suggest that p53 affects AhR-dependent gene expression... | BeFree | 24736433 | Detail |
| 0.007 | Carcinogenesis | The present study was designed to elucidate the role of the aryl hydrocarbon rec... | BeFree | 25523818 | Detail |
| <0.001 | Tumor Initiation | NA | BeFree | Detail | |
| 0.002 | prostate carcinoma | NA | BeFree | Detail | |
| <0.001 | Hot flushes | NA | BeFree | Detail | |
| <0.001 | Epithelial ovarian cancer | NA | BeFree | Detail | |
| 0.012 | breast carcinoma | Depletion of the aryl hydrocarbon receptor in MDA-MB-231 human breast cancer cel... | BeFree | 24932473 | Detail |
| 0.012 | breast carcinoma | DIM is an aryl hydrocarbon receptor (AhR) ligand and a potential anticancer agen... | BeFree | 25048790 | Detail |
| 0.012 | breast carcinoma | A novel compound, NK150460, exhibits selective antitumor activity against breast... | BeFree | 25522763 | Detail |
| 0.012 | breast carcinoma | Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers D... | BeFree | 25781201 | Detail |
| 0.003 | Carcinoma of lung | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of gastrointestinal tract | NA | BeFree | Detail | |
| <0.001 | colon carcinoma | NA | BeFree | Detail | |
| 0.001 | stomach carcinoma | NA | BeFree | Detail | |
| <0.001 | Central neuroblastoma | NA | BeFree | Detail | |
| 0.120 | congenital nystagmus | NA | CTD_human | Detail | |
| <0.001 | Dissecting aneurysm of the thoracic aorta | NA | BeFree | Detail | |
| <0.001 | Middle Cerebral Artery Occlusion | Finally, we have also found that L-kynurenine, a tryptophan metabolite with AhR ... | BeFree | 25359166 | Detail |
| <0.001 | Malignant neoplasm of kidney | NA | BeFree | Detail | |
| <0.001 | Ovarian failure | NA | BeFree | Detail | |
| <0.001 | Sleep Disorders | NA | BeFree | Detail | |
| <0.001 | Carcinogenicity | NA | BeFree | Detail | |
| 0.120 | Drug-Induced Liver Injury | NA | CTD_human | Detail | |
| <0.001 | Sleeplessness | NA | BeFree | Detail | |
| <0.001 | ovarian neoplasm | NA | BeFree | Detail | |
| <0.001 | Vascular inflammations | NA | BeFree | Detail | |
| <0.001 | Polyp of large intestine | NA | BeFree | Detail | |
| <0.001 | Arthritis, Collagen-Induced | NA | BeFree | Detail | |
| 0.120 | Arthritis, Experimental | NA | CTD_human | Detail | |
| <0.001 | Malignant neoplasm of ovary | NA | BeFree | Detail | |
| <0.001 | Squamous cell carcinoma of the head and neck | NA | BeFree | Detail | |
| <0.001 | sarcoma | NA | BeFree | Detail | |
| <0.001 | Uroporphyrinuria | NA | BeFree | Detail | |
| 0.002 | Systemic arterial pressure | NA | GAD | Detail | |
| <0.001 | Precursor B-cell lymphoblastic leukemia | NA | BeFree | Detail | |
| <0.001 | Eosinophilic disorder | NA | BeFree | Detail | |
| <0.001 | Hormone refractory prostate cancer | NA | BeFree | Detail | |
| <0.001 | renal carcinoma | NA | BeFree | Detail | |
| 0.003 | Penis agenesis | NA | BeFree,GAD | Detail | |
| 0.127 | Mammary Neoplasms | NA | BeFree,CTD_human,LHGDN | Detail | |
| <0.001 | Hepatocarcinogenesis | NA | BeFree | Detail | |
| <0.001 | Mammary Tumorigenesis | NA | BeFree | Detail | |
| <0.001 | Skin Carcinogenesis | NA | BeFree | Detail | |
| <0.001 | Tumor Immunity | These results suggest that AhR regulates the invasion of ccRCC and may be involv... | BeFree | 25523818 | Detail |
| <0.001 | Tumor Promotion | NA | BeFree | Detail | |
| <0.001 | Xenograft Model | NA | BeFree | Detail | |
| 0.005 | colorectal cancer | NA | BeFree,GAD | Detail | |
| <0.001 | Non-Malignant Ascites Adverse Event | NA | BeFree | Detail | |
| <0.001 | Adenocarcinoma, Endometrioid | NA | BeFree | Detail | |
| <0.001 | Disorder characterized by eosinophilia | NA | BeFree | Detail | |
| <0.001 | Benign Prostatic Hyperplasia | NA | BeFree | Detail | |
| <0.001 | VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding) | NA | BeFree | Detail | |
| <0.001 | uterine corpus cancer | Aryl hydrocarbon receptor exogenous ligand 3-methylchoranthrene inhibited endome... | BeFree | 24817304 | Detail |
| <0.001 | Precursor Cell Lymphoblastic Leukemia Lymphoma | NA | BeFree | Detail | |
| <0.001 | Urothelial Carcinoma | NA | BeFree | Detail | |
| 0.006 | liver carcinoma | We examined the expression kinetics of some of the aryl hydrocarbon receptor (Ah... | BeFree | 25637755 | Detail |
| <0.001 | Steatohepatitis | NA | BeFree | Detail | |
| 0.120 | Pancreatic cancer, adult | NA | CTD_human | Detail | |
| <0.001 | Clear-cell metastatic renal cell carcinoma | Therefore, inhibiting the activation of AhR may represent a potentially attracti... | BeFree | 25523818 | Detail |
| <0.001 | Triple Negative Breast Neoplasms | NA | BeFree | Detail | |
| <0.001 | Melanocytic nevus of skin | NA | BeFree | Detail | |
| 0.004 | adenocarcinoma | NA | BeFree,LHGDN | Detail | |
| 0.003 | Alzheimer's disease | NA | BeFree,GAD | Detail | |
| <0.001 | Angina, Unstable | Compared with the controls, circulating AhR expression was found to be significa... | BeFree | 25620626 | Detail |
| 0.003 | Anoxia | NA | LHGDN | Detail | |
| <0.001 | arteriosclerosis | NA | BeFree | Detail | |
| <0.001 | arthritis | NA | BeFree | Detail | |
| 0.121 | rheumatoid arthritis | NA | BeFree,CTD_human | Detail | |
| 0.002 | asthma | We used a murine model for ovalbumin (OVA)-induced asthma to examine the effect ... | BeFree | 24819718 | Detail |
| 0.121 | atherosclerosis | NA | BeFree,CTD_human | Detail | |
| 0.001 | Autoimmune Diseases | NA | BeFree | Detail | |
| 0.002 | azoospermia | NA | GAD | Detail | |
| 0.120 | Urinary Bladder Calculi (disorder) | NA | CTD_human | Detail | |
| 0.007 | Malignant neoplasm of urinary bladder | NA | BeFree,GAD | Detail | |
| 0.120 | Bone Resorption | NA | CTD_human | Detail | |
| <0.001 | borderline personality disorder | NA | BeFree | Detail | |
| <0.001 | Brain Neoplasms | NA | BeFree | Detail | |
| 0.027 | Malignant neoplasm of breast | Depletion of the aryl hydrocarbon receptor in MDA-MB-231 human breast cancer cel... | BeFree,GAD | 24932473 | Detail |
| 0.027 | Malignant neoplasm of breast | DIM is an aryl hydrocarbon receptor (AhR) ligand and a potential anticancer agen... | BeFree,GAD | 25048790 | Detail |
| 0.027 | Malignant neoplasm of breast | A novel compound, NK150460, exhibits selective antitumor activity against breast... | BeFree,GAD | 25522763 | Detail |
| 0.027 | Malignant neoplasm of breast | Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers D... | BeFree,GAD | 25781201 | Detail |
| <0.001 | bronchopulmonary dysplasia | NA | BeFree | Detail | |
| <0.001 | Malignant tumor of colon | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of endometrium | Aryl hydrocarbon receptor exogenous ligand 3-methylchoranthrene inhibited endome... | BeFree | 24817304 | Detail |
| <0.001 | mucinous adenocarcinoma | NA | BeFree | Detail | |
| <0.001 | Non-small cell lung carcinoma | NA | BeFree | Detail | |
| <0.001 | renal cell carcinoma | RCC cell lines were exposed to indirubin or 2,3,7,8-tetrachlorodibenzo-p-dioxin ... | BeFree | 25523818 | Detail |
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| AHR-related compounds might be the new and promising therapeutic medicaments for the treatment of pa... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| We examined the expression kinetics of some of the aryl hydrocarbon receptor (AhR)-regulated genes i... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Collectively, these data implicate polycyclic aromatic hydrocarbons and AhR in the regulation of p53... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Although AHR has been found differently expressed in pituitary adenomas, AHR gene mutation status ha... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| L-kynurenine/aryl hydrocarbon receptor pathway mediates brain damage after experimental stroke. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| It is particularly interesting that BCL6 - regulated by AhR/ARNT and wild-type MEF2B - may drive exp... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| We assessed polymorphisms in the aryl hydrocarbon receptor (AhR-Arg554Lys), null variants of the glu... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In conclusion AhR knockdown alters the expression of genes known to enhance or inhibit cancer progre... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Collectively, our findings identify AhR as a regulator of multiple pathogenic pathways in experiment... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Activation of aryl hydrocarbon receptor promotes invasion of clear cell renal cell carcinoma and is ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In this study, we evaluated patients with apparently sporadic GH-secreting pituitary adenoma for AHR... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Aryl hydrocarbon receptor exogenous ligand 3-methylchoranthrene inhibited endometrial cancer cells p... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Aryl hydrocarbon receptor (AHR) pathway has a key role in cellular detoxification mechanisms and see... | DisGeNET | Detail |
| Collectively, our results suggest that p53 affects AhR-dependent gene expression, PAH metabolism, an... | DisGeNET | Detail |
| The present study was designed to elucidate the role of the aryl hydrocarbon receptor (AhR), a major... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Depletion of the aryl hydrocarbon receptor in MDA-MB-231 human breast cancer cells altered the expre... | DisGeNET | Detail |
| DIM is an aryl hydrocarbon receptor (AhR) ligand and a potential anticancer agent, namely for the tr... | DisGeNET | Detail |
| A novel compound, NK150460, exhibits selective antitumor activity against breast cancer cell lines t... | DisGeNET | Detail |
| Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers DNA Damage in Human B... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Finally, we have also found that L-kynurenine, a tryptophan metabolite with AhR agonistic properties... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| These results suggest that AhR regulates the invasion of ccRCC and may be involved in tumor immunity... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Aryl hydrocarbon receptor exogenous ligand 3-methylchoranthrene inhibited endometrial cancer cells p... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| We examined the expression kinetics of some of the aryl hydrocarbon receptor (AhR)-regulated genes i... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Therefore, inhibiting the activation of AhR may represent a potentially attractive therapeutic targe... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Compared with the controls, circulating AhR expression was found to be significantly increased in pa... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| We used a murine model for ovalbumin (OVA)-induced asthma to examine the effect of intranasal delive... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Depletion of the aryl hydrocarbon receptor in MDA-MB-231 human breast cancer cells altered the expre... | DisGeNET | Detail |
| DIM is an aryl hydrocarbon receptor (AhR) ligand and a potential anticancer agent, namely for the tr... | DisGeNET | Detail |
| A novel compound, NK150460, exhibits selective antitumor activity against breast cancer cell lines t... | DisGeNET | Detail |
| Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers DNA Damage in Human B... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Aryl hydrocarbon receptor exogenous ligand 3-methylchoranthrene inhibited endometrial cancer cells p... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| RCC cell lines were exposed to indirubin or 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), AhR ligands,... | DisGeNET | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- dbSNP
- rs386493716 dbSNP
- Genome
- hg19
- Position
- chr7:17,171,814-17,385,774
- Variant Type
- snv
Genome browser